Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
Status:
Withdrawn
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of two
ISIS 113715 subcutaneous doses (15 mg and 30 mg/day) in combination with oral antidiabetic
agents (OAD) versus OAD + placebo in patients with inadequately controlled type 2 diabetes,
despite ongoing maximal treatment with OAD.